German diagnostics developer, Mainz Biomed, has debuted top-line data from the ColoFuture study of its colorectal cancer diagnostic, ColoAlert.
ColoFuture enrolled over 600 patients from cancer centers in Germany, Norway, and Denmark who either were receiving a colonoscopy or had been diagnosed with colorectal adenocarcinoma but had not yet...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?